Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Trial status (May 2026): Eli Lilly reported positive topline results from the Phase 3 TRIUMPH-1 obesity trial on May 21, 2026, with mean weight reduction of 28.3% at 80 weeks on the 12 mg arm [1][2]
[21] However, it is important to note that these findings are preliminary, many are based on animal or in vitro studies, and there is no official link established between allulose consumption and clinically significant enhancement of GLP-1 activity in humans
OrderlyMeds does not accept insurance for any treatments, including branded Wegovy or Zepbound
Over the same window, the healthy weight share rose from 25.1% to 25.6%
No retatrutide has not yet received approval from the MHRA or EMA and is not available on the NHS
Risks of Obesity: The Dark Side of the Story Behind the curtain, obesity is a villain with a twisted backstory
